Navigation Links
Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
Date:1/12/2009

HAYWARD, Calif., Jan. 12 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that it has completed enrollment in its 500 patient FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib (A-002) when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.

"We are pleased with the continued progress of our varespladib cardiovascular program targeting secretory phospholipase A2," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"With the varespladib trial fully enrolled, we look forward to reporting the biomarker results and event trends later this year," said Colin Hislop, M.D., Senior Vice President of Clinical Development at Anthera Pharmaceuticals, Inc. "Based upon the positive results from varespladib's two previous Phase II clinical trials that demonstrated lipid-lowering and anti- inflammatory benefits, we look forward to examining the impact of varespladib on the hyper-inflammatory state presented by ACS patients."

Anthera's FRANCIS trial is based upon direct feedback from FDA via the Special Protocol Assessment procedure. The trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. Anthera plans to enroll between 500-700 patients that will be treated for up to six months. The study is being conducted at sites across North America and Europe. The FRANCIS trial is expected to provide further insight into the prevention of secondary Major
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... (PRWEB) April 25, 2015 Join us ... 29th: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ... of inhibitor residence times is increasingly being incorporated into ... can result in improved efficacy, increased therapeutic window and ... determined using immobilized ligand methods such surface plasmon resonance, ...
(Date:4/24/2015)... Top student social innovators from the ... universities, including UCSD and SDSU, will pitch their impact ... national and nonprofit companies for an opportunity to win ... Social Innovation Challenge 2015 . , The 2015 Social ... addressing a diverse range of issues including poverty, education, ...
(Date:4/24/2015)... SD and Tempe, AZ (PRWEB) April 24, 2015 ... Technology and Arizona State University (ASU) have entered into ... joint projects. , A memorandum of agreement signed by ... long distance learning, student success and other services particularly, ... resources. , “We have complementary strengths and a ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 ... key milestones in its allogeneic stem-cell product development ... to properly reflect the corporate strategic direction. , ... allogeneic (donor) adipose stem cell development program has ... of our cGMP manufacturing facility and hiring of ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2
... 28 Boston,Scientific Corporation (NYSE: BSX ) ... that Boston Scientific has completed its acquisition of ... April 16.,Under the terms of the transaction, all ... per share in cash, for a total of,approximately ...
... N.J., May 28 National Stem Cell,Holding, Inc. (OTC: ... steps to,change its name to Proteonomix, Inc. The change ... Michael Cohen, President/CEO, stated: "Our new name reflects the ... development stage and,commencing the commercialization of our technologies. These ...
... Provides Additional Global Corporate Finance, Management and ... Manufacturing ... (TSX: NVN) announced today the appointment of Gordon H.,Busenbark to ... chief financial officer of Xytis Pharmaceuticals, a privately,held development-stage specialty ...
Cached Biology Technology:Boston Scientific Completes Acquisition of CryoCor 2Boston Scientific Completes Acquisition of CryoCor 3National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 3Nventa Appoints Gordon H. Busenbark to Board of Directors 2
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Fluctuations in penguin populations in the Antarctic are linked more ... to changes in their habitats, according to a new study ... Academy of Sciences . Funded in part by the Lenfest ... "winners" of changing conditions, such as large-scale ice melting, may ...
... NEW YORK (April 11, 2011) -- Weill Cornell Medical ... Surgeons have announced that The Mortimer D. Sackler, M.D. ... awarded to The Rockefeller University,s Dr. Fernando Nottebohm for ... the discovery of neuronal replacement. Dr. Nottebohm is ...
... FINDINGS: Certain differentiated cells in breast tissue can spontaneously ... researchers. Until now, scientific dogma has stated that differentiation ... return to the flexible stem-cell state on their own. ... well as for breast cancer cells. RELEVANCE: ...
Cached Biology News:Penguins that shun ice still lose big from a warming climate 2Sackler Prize awarded to pioneering neuroscientist 2Sackler Prize awarded to pioneering neuroscientist 3Scientists identify a surprising new source of cancer stem cells 2Scientists identify a surprising new source of cancer stem cells 3
MAb to Vasopressin Preservative: NaN3...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... bottoms,• Nonreversible lids with ... contamination,• Individual alphanumerical codes ... footprint for ease in ... cell attachment,• Sterilized by ...
... a G1 cyclin required for G1-phase progression ... proto-oncogene. cyclin D2 can phosphorylate pRB ... Reactivity: Human, Mouse, and Rat. ... particularly well suited for neutralization of cyclin ...
Biology Products: